Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06029894 · ClinicalTrials.gov registry record · NA

Improving Sleep and AD Biomarkers

A NA study, sponsored by Emory University.

Completed
Registry status
NA
Development phase
100
Enrollment target

NCT06029894 is a NA study that has completed, run by Emory University. The registered enrollment target is 100 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06029894, a NA study, has completed, sponsored by Emory University.

COMPLETED
Registry status
NA
Development phase
100 participants
Enrollment target

Study Summary

The purpose of this research is to learn whether a dietary citicoline supplement will impact sleep and cognition. Cognitive disorders include such things as memory disorders and mild cognitive impairment. The investigators are studying persons with mild cognitive impairment (MCI). For this population, the team will assess whether citicoline also impacts biomarkers, a marker of the patient's biological state, in their body. The investigators are interested in learning more about a dietary supplement called citicoline and how it helps sleep, cognition, and markers of Alzheimer's. Previous studies have evaluated this dietary supplement and shown that citicoline may impact cognitive decline. The investigator would like to evaluate if citicoline will also impact sleep and markers of Alzheimer's. This dietary supplement has been assessed in older adults and found to be well tolerated. Citicoline has been used safely in cognitive impairment populations at the same dosage.

Interventions

  • OTHER Placebo
  • DIETARY_SUPPLEMENT Citicoline Supplement

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2023-12-15
Est. Completion 2025-12-21
Phase NA

Sponsor

Emory University

1,208 total trials

What the Registry Record Tells You About NCT06029894

The ClinicalTrials.gov registry entry for NCT06029894 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT06029894 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT06029894 about?

NCT06029894 is a clinical study titled "Improving Sleep and AD Biomarkers". The purpose of this research is to learn whether a dietary citicoline supplement will impact sleep and cognition. Cognitive disorders include such things as memory disorders and mild cognitive impairment. The investigators are studying persons with mild cognitive impairment (MCI). For this populatio...

What is the current status of trial NCT06029894?

This trial is currently completed. It is a NA study. The enrollment target is 100 participants. The study started on 2023-12-15. Estimated completion is 2025-12-21.

What interventions are being tested in trial NCT06029894?

The interventions under investigation include: Placebo (OTHER), Citicoline Supplement (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT06029894?

This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.